177 related articles for article (PubMed ID: 24760634)
1. [Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors].
Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):309-11. PubMed ID: 24760634
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
4. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
5. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
Kikuchi H; Setoguchi T; Miyazaki S; Yamamoto M; Ohta M; Kamiya K; Sakaguchi T; Konno H
Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667
[TBL] [Abstract][Full Text] [Related]
6. Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes.
Marano L; Boccardi V; Marrelli D; Roviello F
Eur J Surg Oncol; 2015 Jul; 41(7):814-22. PubMed ID: 25956211
[TBL] [Abstract][Full Text] [Related]
7. Management of recurrent gastrointestinal stromal tumors.
Winer JH; Raut CP
J Surg Oncol; 2011 Dec; 104(8):915-20. PubMed ID: 21337345
[TBL] [Abstract][Full Text] [Related]
8. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
[TBL] [Abstract][Full Text] [Related]
9. [A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib].
Takeda Y; Nakahira S; Katsura Y; Ohmura Y; Kusama H; Kuroda Y; Goto T; Hashimoto T; Kimura K; Matsushita K; Sato Y; Morimoto Y; Ishida T; Nitta K; Kagawa Y; Okishiro M; Takeno A; Sakisaka H; Taniguchi H; Egawa C; Ohzono K; Nakatsuka S; Kato T; Tamura S
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1545-7. PubMed ID: 25731247
[TBL] [Abstract][Full Text] [Related]
10. [Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].
Shi Y; Liang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):321-5. PubMed ID: 24760637
[TBL] [Abstract][Full Text] [Related]
11. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
Reichardt P; Reichardt A
Zentralbl Chir; 2011 Aug; 136(4):359-63. PubMed ID: 21863513
[TBL] [Abstract][Full Text] [Related]
12. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
[No Abstract] [Full Text] [Related]
13. Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy.
Sakakura C; Hagiwara A; Soga K; Miyagawa K; Nakashima S; Yoshikawa T; Kin S; Nakase Y; Yamaoka N; Sagara Y; Yamagishi H
World J Gastroenterol; 2006 May; 12(17):2793-7. PubMed ID: 16718773
[TBL] [Abstract][Full Text] [Related]
14. GEIS guidelines for gastrointestinal sarcomas (GIST).
Poveda A; García Del Muro X; López-Guerrero JA; Cubedo R; Martínez V; Romero I; Serrano C; Valverde C; Martín-Broto J;
Cancer Treat Rev; 2017 Apr; 55():107-119. PubMed ID: 28351781
[TBL] [Abstract][Full Text] [Related]
15. Current management of gastrointestinal stromal tumors--a comprehensive review.
Lai EC; Lau SH; Lau WY
Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
[TBL] [Abstract][Full Text] [Related]
16. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
Lyseng-Williamson KA
BioDrugs; 2013 Oct; 27(5):525-31. PubMed ID: 23975637
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
George S; Wang Q; Heinrich MC; Corless CL; Zhu M; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Tap WD; Yap JT; Van den Abbeele AD; Manola JB; Solomon SM; Fletcher JA; von Mehren M; Demetri GD
J Clin Oncol; 2012 Jul; 30(19):2401-7. PubMed ID: 22614970
[TBL] [Abstract][Full Text] [Related]
19. Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy.
Takaki H; Litchman T; Covey A; Cornelis F; Maybody M; Getrajdman GI; Sofocleous CT; Brown KT; Solomon SB; Alago W; Erinjeri JP
J Gastrointest Cancer; 2014 Dec; 45(4):494-9. PubMed ID: 25358551
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of regorafenib in colorectal cancer and GIST.
Waddell T; Cunningham D
Lancet; 2013 Jan; 381(9863):273-5. PubMed ID: 23177516
[No Abstract] [Full Text] [Related]
[Next] [New Search]
